Postmenopausal estrogen therapy and depressive symptoms in older women |
| |
Authors: | Mary A. Whooley MD Deborah Grady MD MPH Jane A. Cauley |
| |
Affiliation: | (1) the Section of General Internal Medicine, San Francisco Department of Veterans Affairs Medical Center, Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco, Calif;(2) Department of Epidemiology, University of Pittsburgh, Pittsburgh, Penn |
| |
Abstract: | BACKGROUND: Evidence regarding the effect of postmenopausal estrogen therapy on mood is limited. METHODS: To determine whether postmenopausal estrogen therapy is associated with fewer depressive symptoms in elderly women, we conducted a cross-sectional study of 6,602 white women ages 71 years or older who were recruited from population-based listings in Baltimore, Md; Minneapolis, Minn; Portland, Ore; and the Monongahela Valley, Pa. Use of estrogen and progestin was determined by interview. Participants completed the Geriatric Depression Scale short form (GDS) and were considered depressed if they reported 6 or more of 15 possible symptoms of depression. RESULTS: A total of 6.3% (72/1,150) of current estrogen users, 7.2% (142/1,964) of past estrogen users, and 9.0% (313/3,488) of never users reported 6 or more symptoms of depression (P=.004). Current estrogen users had a decreased risk of reporting 6 or more depressive symptoms, compared with not current (past or never) users of estrogen (odds ratio [OR], 0.7; 95% CI, 0.5 to 0.9; P=.01), adjusted for living alone, bilateral oophorectomy, current smoking, physical activity, social network, self-perceived health, cognitive function, functional status, and antidepressant use. However, excluding women who use estrogen or progestin alone, we were unable to find an association between current use of combined estrogen plus progestin therapy and depressive symptoms (adjusted OR, 0.8; 95% CI, 0.5 to 1.4; P=.5). CONCLUSIONS: This cross-sectional study found that current use of unopposed estrogen was associated with a decreased risk of depressive symptoms in older women. Additional studies are needed to understand the effect of combined estrogen and progestin therapy on the prevalence of depressive symptoms in older women. The members of the Study of Osteoporotic Fractures Research Group are listed in the Appendix. Dr. Whooley is supported by a Research Career Development Award from the Department of Veterans Affairs Health Services Research and Development Service. This study was supported by a grant from the American Federation for Aging Research and by Public Health Service grants AG05394, AG05407, AR35582, AR35583, AR35584, and NS36016. |
| |
Keywords: | depression estrogen replacement therapy aged follow-up studies |
本文献已被 PubMed SpringerLink 等数据库收录! |
|